Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Challenges and Opportunities With Oncology Drug Development in China.

Bajaj G, Gupta M, Heidi Wang HG, Barrett JS, Tan M, Rupalla K, Bertz R, Sheng J.

Clin Pharmacol Ther. 2018 Jan 12. doi: 10.1002/cpt.1017. [Epub ahead of print] Review. No abstract available.

PMID:
29328503
2.

Leveraging Big Data in Pediatric Development Programs: Proceedings From the 2016 American College of Clinical Pharmacology Annual Meeting Symposium.

Mulugeta LY, Yao L, Mould D, Jacobs B, Florian J, Smith B, Sinha V, Barrett JS.

Clin Pharmacol Ther. 2018 Jan 10. doi: 10.1002/cpt.975. [Epub ahead of print] Review.

PMID:
29319159
3.

Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation.

Barrett JS, Bishai R, Bucci-Rechtweg C, Cheung A, Corriol-Rohou S, Haertter S, James A, Kovacs SJ, Liu J, Potempa D, Strougo A, Vanevski K; IQ consortium - CPLG Pediatric Working Group.

Clin Pharmacol Ther. 2018 Mar;103(3):419-433. doi: 10.1002/cpt.1000. Epub 2018 Jan 31. Review.

PMID:
29277892
4.

Questioning the Utility of Breath Testing in Clinical Practice.

Tuck CJ, Yao CK, Philpott HL, Barrett JS.

Am J Gastroenterol. 2017 Dec;112(12):1886. doi: 10.1038/ajg.2017.172. No abstract available.

PMID:
29215609
5.

Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Spitsin S, Tebas P, Barrett JS, Pappa V, Kim D, Taylor D, Evans DL, Douglas SD.

JCI Insight. 2017 Oct 5;2(19). pii: 95893. doi: 10.1172/jci.insight.95893. [Epub ahead of print]

6.

Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.

Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG.

Am J Gastroenterol. 2018 Jan;113(1):124-134. doi: 10.1038/ajg.2017.245. Epub 2017 Aug 15.

PMID:
28809383
7.

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Ming JE, Abrams RE, Bartlett DW, Tao M, Nguyen T, Surks H, Kudrycki K, Kadambi A, Friedrich CM, Djebli N, Goebel B, Koszycki A, Varshnaya M, Elassal J, Banerjee P, Sasiela WJ, Reed MJ, Barrett JS, Azer K.

Gene Regul Syst Bio. 2017 Jun 22;11:1177625017710941. doi: 10.1177/1177625017710941. eCollection 2017.

8.

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.

van Rongen A, Brill MJE, Vaughns JD, Välitalo PAJ, van Dongen EPA, van Ramshorst B, Barrett JS, van den Anker JN, Knibbe CAJ.

Clin Pharmacokinet. 2017 Aug 7. doi: 10.1007/s40262-017-0579-4. [Epub ahead of print]

PMID:
28785981
9.

Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a proof-of-concept study.

Iacovou M, Mulcahy EC, Truby H, Barrett JS, Gibson PR, Muir JG.

J Hum Nutr Diet. 2017 Jun 20. doi: 10.1111/jhn.12488. [Epub ahead of print]

PMID:
28631347
10.

Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders.

Yao CK, Tuck CJ, Barrett JS, Canale KE, Philpott HL, Gibson PR.

United European Gastroenterol J. 2017 Mar;5(2):284-292. doi: 10.1177/2050640616657978. Epub 2016 Jul 7.

11.

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.

Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, Turner MA.

Pediatr Res. 2017 May;81(5):692-711. doi: 10.1038/pr.2016.221. Epub 2016 Nov 3.

PMID:
28248319
12.

How to institute the low-FODMAP diet.

Barrett JS.

J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:8-10. doi: 10.1111/jgh.13686. Review.

PMID:
28244669
13.
14.

Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.

Barrett JS, Spitsin S, Moorthy G, Barrett K, Baker K, Lackner A, Tulic F, Winters A, Evans DL, Douglas SD.

J Transl Med. 2016 May 26;14(1):148. doi: 10.1186/s12967-016-0904-y.

15.

Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.

Mulugeta Y, Barrett JS, Nelson R, Eshete AT, Mushtaq A, Yao L, Glasgow N, Mulberg AE, Gonzalez D, Green D, Florian J, Krudys K, Seo S, Kim I, Chilukuri D, Burckart GJ.

J Clin Pharmacol. 2016 Nov;56(11):1326-1334. doi: 10.1002/jcph.744. Review.

16.

Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.

Stockmann C, Barrett JS, Roberts JK, Sherwin C.

CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):630-40. doi: 10.1002/psp4.12038. Epub 2015 Nov 13.

17.

A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children.

Barrett JS, Hirankarn S, Holford N, Hammer GB, Drover DR, Cohane CA, Anderson B, Dombrowski E, Reece T, Zajicek A, Schulman SR.

Front Pharmacol. 2015 Jul 28;6:151. doi: 10.3389/fphar.2015.00151. eCollection 2015.

18.

Evaluation of sodium nitroprusside for controlled hypotension in children during surgery.

Drover DR, Hammer GB, Barrett JS, Cohane CA, Reece T, Zajicek A, Schulman SR.

Front Pharmacol. 2015 Jul 6;6:136. doi: 10.3389/fphar.2015.00136. eCollection 2015.

19.

Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK.

Pharmacotherapy. 2015 Jul;35(7):670-80. doi: 10.1002/phar.1610. Epub 2015 Jul 14.

20.

Poor predictive value of breath hydrogen response for probiotic effects in IBS.

Yao CK, Barrett JS, Philpott H, Chung AR, van Langenberg D, Garg M, Gibson PR.

J Gastroenterol Hepatol. 2015 Dec;30(12):1731-9. doi: 10.1111/jgh.13015.

PMID:
26095068
21.

Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents.

van Rongen A, Vaughns JD, Moorthy GS, Barrett JS, Knibbe CA, van den Anker JN.

Br J Clin Pharmacol. 2015 Nov;80(5):1185-96. doi: 10.1111/bcp.12693. Epub 2015 Sep 10.

22.

Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.

Harskamp-van Ginkel MW, Hill KD, Becker KC, Testoni D, Cohen-Wolkowiez M, Gonzalez D, Barrett JS, Benjamin DK Jr, Siegel DA, Banks P, Watt KM; Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee.

JAMA Pediatr. 2015 Jul;169(7):678-85. doi: 10.1001/jamapediatrics.2015.132. Review. Erratum in: JAMA Pediatr. 2015 Dec;169(12):1179. Becker, Kristian [corrected to Becker, Kristian C].

23.

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD.

AIDS. 2015 May 15;29(8):931-9. doi: 10.1097/QAD.0000000000000638.

24.

Challenges and considerations for development of therapeutic proteins in pediatric patients.

Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, Gupta M.

J Clin Pharmacol. 2015 Mar;55 Suppl 3:S103-15. doi: 10.1002/jcph.382. Review.

PMID:
25707958
25.

Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency.

Mascarenhas MR, Mondick J, Barrett JS, Wilson M, Stallings VA, Schall JI.

J Clin Pharmacol. 2015 Aug;55(8):854-65. doi: 10.1002/jcph.484. Epub 2015 Mar 23.

26.

Adjuvant therapies for HIV-associated neurocognitive disorders.

McGuire JL, Barrett JS, Vezina HE, Spitsin S, Douglas SD.

Ann Clin Transl Neurol. 2014 Nov;1(11):938-52. doi: 10.1002/acn3.131. Epub 2014 Oct 23. Review.

27.

Novel method to predict body weight in children based on age and morphological facial features.

Huang Z, Barrett JS, Barrett K, Barrett R, Ng CM.

J Clin Pharmacol. 2015 Apr;55(4):447-51. doi: 10.1002/jcph.422. Epub 2015 Jan 6.

PMID:
25370186
28.

Management Strategies for Abdominal Bloating and Distension.

Foley A, Burgell R, Barrett JS, Gibson PR.

Gastroenterol Hepatol (N Y). 2014 Sep;10(9):561-71.

29.

Predictors of arterial blood pressure control during deliberate hypotension with sodium nitroprusside in children.

Spielberg DR, Barrett JS, Hammer GB, Drover DR, Reece T, Cohane CA, Schulman SR.

Anesth Analg. 2014 Oct;119(4):867-74. doi: 10.1213/ANE.0000000000000376.

30.

Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.

Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, Zhao X, Tebas P, Evans DL, Douglas SD.

Curr HIV Res. 2014;12(2):121-31.

PMID:
24862330
31.

Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome.

Tuck CJ, Muir JG, Barrett JS, Gibson PR.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):819-34. doi: 10.1586/17474124.2014.917956. Epub 2014 May 15. Review.

PMID:
24830318
32.

Measurement of the survival probabilities for hot fusion reactions.

Yanez R, Loveland W, Yao L, Barrett JS, Zhu S, Back BB, Khoo TL, Alcorta M, Albers M.

Phys Rev Lett. 2014 Apr 18;112(15):152702. Epub 2014 Apr 17.

PMID:
24785034
33.

ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.

Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZJ, Zhou HH, Pei Q, Guo CX, Wang JL, Yang GP.

Drug Metab Pharmacokinet. 2014;29(4):305-11. Epub 2014 Feb 11.

34.

The grand challenges in obstetric and pediatric pharmacology.

Zajicek A, Barrett JS.

Front Pharmacol. 2013 Dec 30;4:170. doi: 10.3389/fphar.2013.00170. eCollection 2013. No abstract available.

35.

Response to Comment on low FODMAP diet.

Barrett JS, Gibson P.

Nutr Clin Pract. 2013 Dec;28(6):775-6. doi: 10.1177/0884533613503555. No abstract available.

PMID:
24264391
36.

Paediatric models in motion: requirements for model-based decision support at the bedside.

Barrett JS.

Br J Clin Pharmacol. 2015 Jan;79(1):85-96. doi: 10.1111/bcp.12287. Review.

37.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

38.

Functional bowel symptoms and diet.

Gibson PR, Barrett JS, Muir JG.

Intern Med J. 2013 Oct;43(10):1067-74. doi: 10.1111/imj.12266. Review.

PMID:
24134168
39.

Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children.

Jiang XL, Zhao P, Barrett JS, Lesko LJ, Schmidt S.

CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e80. doi: 10.1038/psp.2013.55.

40.

PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?

Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD.

J Clin Psychopharmacol. 2013 Dec;33(6):725-8. doi: 10.1097/JCP.0b013e3182a88654.

PMID:
24100788
41.
42.

Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome.

Yao CK, Tan HL, van Langenberg DR, Barrett JS, Rose R, Liels K, Gibson PR, Muir JG.

J Hum Nutr Diet. 2014 Apr;27 Suppl 2:263-75. doi: 10.1111/jhn.12144. Epub 2013 Aug 3.

PMID:
23909813
43.

A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms.

Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, Lum S, Breitkreutz J, Baltezor M, Macheras P, Khan M, Agharkar S, MacLaren DD.

AAPS J. 2013 Oct;15(4):1072-81. doi: 10.1208/s12248-013-9511-5. Epub 2013 Aug 2. Review.

44.

Letter: oral fructose--breath hydrogen response, symptoms, both or neither?

Barrett JS, Ng PS, Muir JG, Gibson PR.

Aliment Pharmacol Ther. 2013 Aug;38(4):442-3. doi: 10.1111/apt.12392. No abstract available.

45.

Identifying novel phenotypes of vulnerability and resistance to activity-based anorexia in adolescent female rats.

Barbarich-Marsteller NC, Underwood MD, Foltin RW, Myers MM, Walsh BT, Barrett JS, Marsteller DA.

Int J Eat Disord. 2013 Nov;46(7):737-46. doi: 10.1002/eat.22149. Epub 2013 Jul 13.

46.

Considerations for the prediction of survival time in pancreatic cancer based on registry data.

Bajaj G, Dombrowsky E, Yu Q, Agarwal B, Barrett JS.

J Pharmacokinet Pharmacodyn. 2013 Aug;40(4):527-36. doi: 10.1007/s10928-013-9327-z. Epub 2013 Jul 12.

PMID:
23846417
47.

A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.

Srivastava P, Moorthy GS, Gross R, Barrett JS.

PLoS One. 2013 Jun 5;8(6):e63305. doi: 10.1371/journal.pone.0063305. Print 2013.

48.

Commentary: sugar intolerances in functional gastrointestinal disorders.

Barrett JS, Gibson PR.

Aliment Pharmacol Ther. 2013 Jul;38(1):72. doi: 10.1111/apt.12343. No abstract available.

49.

Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms.

Barrett JS.

Nutr Clin Pract. 2013 Jun;28(3):300-6. doi: 10.1177/0884533613485790. Epub 2013 Apr 24. Review.

PMID:
23614962
50.

Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients.

Barrett JS, Patel D, Dombrowsky E, Bajaj G, Skolnik JM.

AAPS J. 2013 Jul;15(3):775-86. doi: 10.1208/s12248-013-9489-z. Epub 2013 Apr 18.

Supplemental Content

Loading ...
Support Center